Overview

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a 12-month single center, randomized, open-label, single center study designed to compare the safety and efficacy of everolimus and very low dose tacrolimus versus enteric-coated sodium mycophenolate and low tacrolimus exposure in de novo kidney transplant recipients. The purpose of this study is to compare safety and efficacy of two immunosuppressive regimens based on low tacrolimus exposure combined to everolimus or to enteric-coated mycophenolate sodium (EC-MPS) in de novo kidney transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
Ronaldo de Matos Esmeraldo, MD
Collaborator:
Novartis Pharmaceuticals
Treatments:
Antilymphocyte Serum
Everolimus
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisone
Sirolimus
Tacrolimus
Thymoglobulin